Directly from the USA: Cancer Vaccine Safe, Induces T-Cell Responses for KRAS-Mutated Tumors

For patients with immunotherapy recalcitrant KRAS-mutated tumors, the cancer vaccine ELI-002 2P is safe and induces T-cell responses, according to a study published online Jan. 9 in Nature Medicine.

Noting that the cancer vaccine ELI-002 2P enhances lymph node delivery and immune response using Amphiphile (Amph)-modification of G12D and G12R mutant KRAS (mKRAS) peptides (Amph-Peptides-2P) together with CpG oligonucleotide adjuvant (Amph-CpG-7909), Shubham Pant, M.D., M.B.B.S., from the University of Texas MD Anderson Cancer Center in Houston, and colleagues treated 25 patients (20 with pancreatic cancer; five with colorectal cancer) positive for minimal residual mKRAS disease after locoregional treatment in a phase 1 study involving fixed-dose Amph-Peptides-2P and ascending dose Amph-CpG-7909.

Source: Advances and More licensed by HealthDay

https://advancesandmore.com/advances_article.htm?id=ODU1ZDZjYmQtNTI5MS00NWY0LTgwNmItZjA5ZTQzYjJjOTBj&client=Nw%3D%3D&section=undefined